# Use of NovoSeven® in Active Variceal Bleeding

> **NCT00154492** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 265 (actual)

## Conditions studied

- Acquired Bleeding Disorder
- Cirrhosis

## Interventions

- **DRUG:** activated recombinant human factor VII

## Key facts

- **NCT ID:** NCT00154492
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2017-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00154492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00154492, "Use of NovoSeven® in Active Variceal Bleeding". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00154492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*